Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1990-05-14
1993-02-23
Bond, Robert T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514400, 514419, 514562, A61K 3170, A61K 31415, A61K 3140, A61K 31195
Patent
active
051890259
ABSTRACT:
Disclosed are total parenteral nutrition formulations which include essential amino acids in combination with either arginine or ornithine, for use in the detection of recurrent malignant disease in patients. Such formulations stimulate tumor-specfic polyamine production to a greater extent than non-tumor related polyamine production. Additionally, such formulations were found to specifically promote an increase in red blood cell putrescine levels of tumor-bearing rats. Nontumor-bearing rats were not found to be similarly reactive to these formulations. Methods for making and administering these formulations as well as their use in preventing DFMO-induced toxicity are also disclosed.
Also disclosed are parenteral nutritional formulations which include both citrulline and ornithine which have an arginine concentration of less than about 0.10% by weight final concentration. These formulations inhibi
REFERENCES:
patent: 3235597 (1956-02-01), Mills et al.
patent: 3236601 (1966-02-01), Harvill
patent: 3764703 (1973-10-01), Bergstrom et al.
patent: 3832465 (1974-08-01), Ghadimi
patent: 3950529 (1976-04-01), Fisher et al.
patent: 4065552 (1977-12-01), Costa
patent: 4444890 (1984-04-01), Burzynski
patent: 4491589 (1985-01-01), Dell et al.
patent: 4542750 (1985-09-01), Ettare
Grossie et al (Jan. 21-24, 1985), 9th Clin. Cong. of Am. Soc. Parenteral and Enteral Nutrition, Abs. 16-17.
Ota et al (1984), J. Clin. Onco., 2(10):1157-64.
Progress in Cancer Research and Therapy, Raven Press, New York, NY (1978).
Grossie et al (1987), Cancer Res., 47:1836-40.
Ota et al (1986), Int. J. Cancer, 38:245-9.
Byus et al (1987), Proc. of AACR, 28:158 (#630).
Nishioka et al (1988), Int. J. Cancer, 42(5):744-7.
Garewal et al (1988), Cancer Research, 48:3288-91.
Majumdar et al (1987), Life Sciences, 41:961-66.
Malo et al (1987), Experientia, 44:251-2.
Morris, J. (1985), J. Nutr., 115:524-31.
Seidel et al (1985), Am. J. Physiol., 249:G434-8.
Luk et al (1984), J. Clin. Invest., 74:698-704.
Lundell et al (1986), Scand. J. Gastroenterology, 21(7):829-32.
J. L. Rombeau & M. D. Caldwell (eds), (1986), In: Parenteral Nutrition 2:100-34.
Braun Amino Acid Suppliers--Combiplasma.RTM. S-3,5 formulation.
Salvia Amino Acid Suppliers--Aminomel.RTM. 10X-E Salvia formulation.
Phimmer Amino Acid Supplers--Comafusion.RTM. llepar formulation.
Dowling et al (1985), Scand. J. Gastroenterol., 20112-84-95.
White et al (1978), Princ. of Biochem., 21:684-700.
Nixon et al (1981), Cancer Treatment Reports, 65(5):121-7.
Luk et al (1983), Am. J. Physiol, 245:G656-60.
Yang et al (1984), Am. J. Physiol., 247:G553-7.
Harris et al (1985), J. Surg. Res., 38592-98.
Tabata et al (1986), Am. J. Physiol., 251:G270-4.
Grosse, et al., (1986), Cancer Research, 46:3464-8.
Zieve, et al., (1986), Metabolic Brain Disease, 1 (1): 25-35.
Fahey, J. L. (1957), J. Clin. Invest. 36: 1647-1655.
Levy et al. (1954), Cancer Res., 14: 198-200.
Grossie et al. (Jan. 1991) 15th Clinical Congress, American Society for Parenteral and Enternalnutrition (Abstract).
Nishioka, et al., Int. J. Cancer, 42:744-747, 1988.
Gonzales, et al. (1991), Cancer Research, 51:2932-2939.
Ajani Jaffer
Grossie, Jr. Bruce
Nishioka Kenji
Ota David M.
Board of Regenets, The University of Texas System
Bond Robert T.
Ward E. C.
LandOfFree
Methods for the treatment of malignant disease in patients using does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of malignant disease in patients using, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of malignant disease in patients using will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2204955